Biotech Showcase™ 2017: Q BioMed plans to accelerate up to four more assets

January 23, 2017
Established in June 2015, Q BioMed, the NYC-based biomedical acceleration development company, is looking to add three to four more assets to its portfolio. Company founder and CEO, Denis Corin, outlines to Mike Ward, Informa Pharma Intelligence’s insights global director of content, the progress Q BioMed has made with its first two assets and details his ambition to expand further in the coming two to three years.
Previous Video
Biotech Showcase™ 2017: Advancing neurokinin receptor antagonists in respiratory and women’s health
Biotech Showcase™ 2017: Advancing neurokinin receptor antagonists in respiratory and women’s health

Starting the year with a cash injection of GDP 23 million, 2012 GSK spin-out NeRRe Therapeutics intends to ...

Next Video
Biotech Showcase™ 2017: Double-barreled approach doubles survival times in recurrent glioma patients
Biotech Showcase™ 2017: Double-barreled approach doubles survival times in recurrent glioma patients

Brain cancer remains one of the deadliest diseases, and little to no effective treatments exist. Marty Duva...